BioNTech SE (BNTX) Tops Q3 EPS, Warns on COVID Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BNTX Hot Sheet
Join SI Premium – FREE
BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR0.67, EUR0.05 better than the analyst estimate of EUR0.62. Revenue for the quarter came in at EUR895.3 million versus the consensus estimate of EUR837.61 million.
GUIDANCE:
Updated 2023 COVID-19 vaccine revenue guidance of around EUR4 billion, versus EUR5 billion prior.
For earnings history and earnings-related data on BioNTech SE (BNTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
- Ovintiv Inc. (OVV) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
